MDCX · Medicus Pharma Ltd. · Insider Trading
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed Aug 12, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-09-04 | Mehmud Faisal |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
250,000 |
| 2026-09-04 | Smith Andrew Alasdair |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
125,000 |
| 2026-09-04 | Bonner Carolyn F. |
President and CFO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
250,000 |
| 2026-09-04 | Brennan Edward J. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
100,000 |
| 2026-09-04 | Bokhari Raza |
Director, Chief Executive Officer |
Award↑
|
Common Shares, no par value
|
2,941,176 |
| 2026-09-04 | Brennan Edward J. |
Chief Scientific Officer |
Award↑
|
Common Shares, no par value
|
588,235 |
| 2026-09-04 | Smith Andrew Alasdair |
Chief Operating Officer |
Award↑
|
Common Shares, no par value
|
735,294 |
| 2026-09-04 | Bonner Carolyn F. |
President and CFO |
Award↑
|
Common Shares, no par value
|
1,470,588 |
| 2026-09-04 | Mehmud Faisal |
Chief Medical Officer |
Award↑
|
Common Shares, no par value
|
1,470,588 |
| 2026-09-04 | Bokhari Raza |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on September 4, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
500,000 |
| 2026-06-03 | Smith Andrew Alasdair |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
200,000 |
| 2026-06-03 | MAHAFFY PATRICK J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Ciaruffoli Robert J. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Kaiser Larry |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Mehmud Faisal |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
250,000 |
| 2026-06-03 | Bokhari Raza |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
500,000 |
| 2026-06-03 | Ashton William |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Brennan Edward J. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2026-06-03 | FISHMAN BARRY |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Bonner Carolyn F. |
President and CFO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
250,000 |
| 2026-06-03 | May Sara R. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Rodgers Cathy McMorris |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-06-03 | Raju Ajay |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2026-03-30 | Kaiser Larry |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | FISHMAN BARRY |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | May Sara R. |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | Smith Andrew Alasdair |
Chief Operating Officer |
Award↑
|
Stock Option (right to buy)
|
50,000 |
| 2026-03-30 | MAHAFFY PATRICK J |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | Rodgers Cathy McMorris |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | Ciaruffoli Robert J. |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | Bokhari Raza |
Director, Chief Executive Officer |
Award↑
|
Stock Option (right to buy)
|
325,000 |
| 2026-03-30 | Mehmud Faisal |
Chief Medical Officer |
Award↑
|
Stock Option (right to buy)
|
125,000 |
| 2026-03-30 | Raju Ajay |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | Ashton William |
Director |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2026-03-30 | Bonner Carolyn F. |
President and CFO |
Award↑
|
Stock Option (right to buy)
|
100,000 |
| 2026-03-30 | Brennan Edward J. |
Chief Scientific Officer |
Award↑
|
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | May Sara R. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | MAHAFFY PATRICK J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | Ciaruffoli Robert J. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | Raju Ajay |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | Mehmud Faisal |
Chief Medical Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
75,000 |
| 2025-12-16 | Rodgers Cathy McMorris |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | Brennan Edward J. |
Chief Scientific Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2025-12-16 | Bonner Carolyn F. |
President and CFO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
75,000 |
| 2025-12-16 | Bokhari Raza |
Director, Chief Executive Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
125,000 |
| 2025-12-16 | Kaiser Larry |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | FISHMAN BARRY |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-12-16 | Smith Andrew Alasdair |
Chief Operating Officer |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
50,000 |
| 2025-12-16 | Ashton William |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. |
Stock Option (right to buy)
|
25,000 |
| 2025-08-13 | Quinlan James P. |
Chief Financial Officer |
Convert↓
Filing footnotes — Stock Option (right to buy) (Direct)
Represents an exercise price of $1.16 Canadian dollars, converted to U.S. dollars at the daily average exchange rate of $1.00 to CAD$1.4379 reported by the Bank of Canada on December 30, 2024. The option was vested and was exercisable as of the Transaction Date. |
Stock Option (right to buy)
|
125,000 |